NASDAQ:MYGN Myriad Genetics (MYGN) Stock Forecast, Price & News $22.29 +0.17 (+0.77%) (As of 05/26/2023 04:00 PM ET) Add Compare Share Share Today's Range$21.88▼$22.7650-Day Range$17.56▼$23.7652-Week Range$13.92▼$28.18Volume396,500 shsAverage Volume592,800 shsMarket Capitalization$1.82 billionP/E RatioN/ADividend YieldN/APrice Target$26.60 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Myriad Genetics MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside19.3% Upside$26.60 Price TargetShort InterestBearish4.62% of Shares Sold ShortDividend StrengthN/ASustainability-0.60Upright™ Environmental ScoreNews Sentiment0.61Based on 20 Articles This WeekInsider TradingSelling Shares$151,047 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.63) to ($0.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.92 out of 5 starsMedical Sector718th out of 1,010 stocksDiagnostic Substances Industry8th out of 16 stocks 2.3 Analyst's Opinion Consensus RatingMyriad Genetics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $26.60, Myriad Genetics has a forecasted upside of 19.3% from its current price of $22.29.Amount of Analyst CoverageMyriad Genetics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.62% of the outstanding shares of Myriad Genetics have been sold short.Short Interest Ratio / Days to CoverMyriad Genetics has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Myriad Genetics has recently increased by 2.45%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMyriad Genetics does not currently pay a dividend.Dividend GrowthMyriad Genetics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMyriad Genetics has received a 58.24% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Genomics analysis tools", "Computerized clinical decision support software", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Myriad Genetics is -0.60. Previous Next 2.6 News and Social Media Coverage News SentimentMyriad Genetics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Myriad Genetics this week, compared to 3 articles on an average week.Search Interest1 people have searched for MYGN on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Myriad Genetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $151,047.00 in company stock.Percentage Held by InsidersOnly 2.00% of the stock of Myriad Genetics is held by insiders.Percentage Held by Institutions99.08% of the stock of Myriad Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Myriad Genetics are expected to grow in the coming year, from ($0.63) to ($0.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Myriad Genetics is -12.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Myriad Genetics is -12.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMyriad Genetics has a P/B Ratio of 2.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Myriad Genetics (NASDAQ:MYGN) StockMyriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.Read More Receive MYGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter. Email Address MYGN Stock News HeadlinesMay 15, 2023 | marketbeat.comExact Sciences Serves Investors Exactly What They Wished For (MYGN)Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ: EXAS) saw its shares spike over 17% on its Q1 2023 earnings results. TheMay 28, 2023 | americanbankingnews.comMyriad Genetics, Inc. (NASDAQ:MYGN) Receives Consensus Rating of "Hold" from AnalystsMay 29, 2023 | Stocks To Trade (Ad)3 Free Stock Picks per DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 25, 2023 | finance.yahoo.comMyriad Genetics (MYGN) Adds New Test to Oncology PortfolioMay 25, 2023 | fool.comMyriad Genetics (NASDAQ: MYGN)May 25, 2023 | 247wallst.comGoldman Sachs Maintains Myriad Genetics Buy RecommendationMay 24, 2023 | tmcnet.comMyriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for WomenMay 24, 2023 | tmcnet.comMyriad Genetics Adds Folate Receptor Alpha to Precise&…May 29, 2023 | Stocks To Trade (Ad)3 Free Stock Picks per DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 24, 2023 | finance.yahoo.comMyriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian CancerMay 24, 2023 | msn.comGoldman Sachs Maintains Myriad Genetics (MYGN) Buy RecommendationMay 23, 2023 | msn.comMyriad Genetics rises as Goldman upgrades on growth potentialMay 23, 2023 | msn.comGoldman Sachs Upgrades Myriad Genetics (MYGN)May 23, 2023 | finance.yahoo.comMyriad Genetics Stock Soars on Double Upgrade From GoldmanMay 23, 2023 | msn.comLilium, Myriad Genetics And Other Big Stocks Moving Higher In Tuesday's Pre-Market SessionMay 23, 2023 | markets.businessinsider.comPositive Report for Myriad Genetics (MYGN) from Goldman SachsMay 23, 2023 | finance.yahoo.com4 big analyst picks: Battered regional banks becoming buysMay 23, 2023 | americanbankingnews.comMyriad Genetics (NASDAQ:MYGN) Upgraded to "Buy" by The Goldman Sachs GroupMay 9, 2023 | marketwatch.comMyriad Genetics Earns 2023 Great Place to Work Certification(TM)May 8, 2023 | finance.yahoo.comMyriad Genetics Earns 2023 Great Place to Work Certification™May 6, 2023 | benzinga.comMyriad Genetics Stock (NASDAQ:MYGN), Short Interest ReportMay 5, 2023 | finance.yahoo.comMyriad Genetics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsMay 4, 2023 | msn.comStephens & Co. Reiterates Myriad Genetics (MYGN) Equal-Weight RecommendationMay 4, 2023 | msn.comGoldman Sachs Maintains Myriad Genetics (MYGN) Sell RecommendationMay 4, 2023 | markets.businessinsider.comWhere Myriad Genetics Stands With AnalystsMay 4, 2023 | markets.businessinsider.comRaymond James Reaffirms Their Buy Rating on Myriad Genetics (MYGN)May 4, 2023 | finance.yahoo.comQ1 2023 Myriad Genetics Inc Earnings CallSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MYGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter. Email Address MYGN Company Calendar Last Earnings5/03/2023Today5/29/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:MYGN CUSIP62855J10 CIK899923 Webwww.myriad.com Phone(801) 584-3600Fax801-584-3640Employees2,600Year Founded1991Price Target and Rating Average Stock Price Forecast$26.60 High Stock Price Forecast$32.00 Low Stock Price Forecast$24.00 Forecasted Upside/Downside+19.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,000,000.00 Net Margins-21.05% Pretax Margin-24.01% Return on Equity-7.42% Return on Assets-5.55% Debt Debt-to-Equity RatioN/A Current Ratio1.83 Quick Ratio1.67 Sales & Book Value Annual Sales$678.40 million Price / Sales2.68 Cash Flow$0.19 per share Price / Cash Flow116.25 Book Value$10.93 per share Price / Book2.04Miscellaneous Outstanding Shares81,560,000Free Float79,924,000Market Cap$1.82 billion OptionableOptionable Beta1.84 Social Links Key ExecutivesPaul J. DiazPresident, Chief Executive Officer & DirectorNicole LambertChief Operating OfficerR. Bryan RiggsbeeChief Financial Officer, Treasurer & Executive VPDale MuzzeyChief Scientific OfficerKevin R. HaasChief Technology OfficerKey CompetitorsCelldex TherapeuticsNASDAQ:CLDXHeskaNASDAQ:HSKANeogenNASDAQ:NEOGIntellia TherapeuticsNASDAQ:NTLAQuidelOrthoNASDAQ:QDELView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 2,109 shares on 5/26/2023Ownership: 0.021%Ameriprise Financial Inc.Sold 7,749 shares on 5/22/2023Ownership: 0.381%JPMorgan Chase & Co.Bought 17,176 shares on 5/18/2023Ownership: 0.194%New York State Common Retirement FundSold 38,933 shares on 5/18/2023Ownership: 0.155%Thrivent Financial for LutheransSold 2,814 shares on 5/17/2023Ownership: 0.098%View All Insider TransactionsView All Institutional Transactions MYGN Stock - Frequently Asked Questions Should I buy or sell Myriad Genetics stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MYGN shares. View MYGN analyst ratings or view top-rated stocks. What is Myriad Genetics' stock price forecast for 2023? 4 brokerages have issued 12-month target prices for Myriad Genetics' shares. Their MYGN share price forecasts range from $24.00 to $32.00. On average, they predict the company's stock price to reach $26.60 in the next twelve months. This suggests a possible upside of 19.3% from the stock's current price. View analysts price targets for MYGN or view top-rated stocks among Wall Street analysts. How have MYGN shares performed in 2023? Myriad Genetics' stock was trading at $14.51 at the beginning of 2023. Since then, MYGN shares have increased by 53.6% and is now trading at $22.29. View the best growth stocks for 2023 here. When is Myriad Genetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our MYGN earnings forecast. How were Myriad Genetics' earnings last quarter? Myriad Genetics, Inc. (NASDAQ:MYGN) posted its quarterly earnings data on Wednesday, May, 3rd. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by $0.02. The company had revenue of $181.20 million for the quarter, compared to analyst estimates of $171.56 million. Myriad Genetics had a negative trailing twelve-month return on equity of 7.42% and a negative net margin of 21.05%. The company's quarterly revenue was up 9.9% on a year-over-year basis. During the same period last year, the company posted ($0.14) earnings per share. What ETFs hold Myriad Genetics' stock? ETFs with the largest weight of Myriad Genetics (NASDAQ:MYGN) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Invesco S&P SmallCap Health Care ETF (PSCH), WisdomTree BioRevolution Fund (WDNA), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI), Vanguard S&P Small-Cap 600 Value ETF (VIOV) and SPDR S&P 600 Small CapValue ETF (SLYV). What guidance has Myriad Genetics issued on next quarter's earnings? Myriad Genetics issued an update on its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided EPS guidance of -$0.36--$0.24 for the period, compared to the consensus EPS estimate of -$0.32. The company issued revenue guidance of $730.00 million-$750.00 million, compared to the consensus revenue estimate of $732.49 million. What is Paul Diaz's approval rating as Myriad Genetics' CEO? 12 employees have rated Myriad Genetics Chief Executive Officer Paul Diaz on Glassdoor.com. Paul Diaz has an approval rating of 74% among the company's employees. What other stocks do shareholders of Myriad Genetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AT&T (T), Alibaba Group (BABA) and Kratos Defense & Security Solutions (KTOS). What is Myriad Genetics' stock symbol? Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN." Who are Myriad Genetics' major shareholders? Myriad Genetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (17.32%), Wellington Management Group LLP (8.25%), State Street Corp (5.64%), Glenview Capital Management LLC (5.14%), Bank of America Corp DE (4.21%) and Dimensional Fund Advisors LP (3.34%). Insiders that own company stock include Alexander Ford, Daniel K Spiegelman, Dennis Langer, Jayne B Hart, Jerry S Lanchbury, Jerry S Lanchbury, Nicole Lambert, Paul Parkinson, Richard Bryan Riggsbee and S Louise Phanstiel. View institutional ownership trends. How do I buy shares of Myriad Genetics? Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Myriad Genetics' stock price today? One share of MYGN stock can currently be purchased for approximately $22.29. How much money does Myriad Genetics make? Myriad Genetics (NASDAQ:MYGN) has a market capitalization of $1.82 billion and generates $678.40 million in revenue each year. The company earns $-112,000,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis. How many employees does Myriad Genetics have? The company employs 2,600 workers across the globe. Does Myriad Genetics have any subsidiaries? The following companies are subsidiares of Myriad Genetics: Assurex Health Inc., Assurex Health Ltd, Counsyl, Crescendo Bioscience, Crescendo Bioscience LLC, Javelin Pharmaceuticals, Myriad Autoimmune, Myriad Genetic Laboratories Inc., Myriad Genetics Australia PTY LTD, Myriad Genetics B.V., Myriad Genetics Canada Corp, Myriad Genetics Espana SL, Myriad Genetics GK, Myriad Genetics GmbH, Myriad Genetics LTD, Myriad Genetics S.r.l., Myriad Genetics SAS, Myriad GmbH, Myriad International GmbH, Myriad Neuroscience, Myriad Services GmbH, Myriad Women’s Health, Myriad Women’s Health Inc, NaturNorth Technologies, Privatklinik Dr. Robert Schindlbeck, Rules-Based Medicine, and Sividon Diagnostics.Read More How can I contact Myriad Genetics? Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The official website for the company is www.myriad.com. The company can be reached via phone at (801) 584-3600, via email at sgleason@myriad.com, or via fax at 801-584-3640. This page (NASDAQ:MYGN) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.